Rani Therapeutics Holdings Inc
RANI1.510USD
-0.010-0.66%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
72.39MMarket Cap
LossP/E TTM
More Details of Rani Therapeutics Holdings Inc Company
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Rani Therapeutics Holdings Inc Info
Ticker SymbolRANI
Company nameRani Therapeutics Holdings Inc
IPO dateJul 30, 2021
CEOImran (Talat)
Number of employees105
Security typeOrdinary Share
Fiscal year-endJul 30
Address2051 Ringwood Avenue
CitySAN JOSE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code95131
Phone14084573700
Websitehttps://www.ranitherapeutics.com/
Ticker SymbolRANI
IPO dateJul 30, 2021
CEOImran (Talat)
Company Executives of Rani Therapeutics Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Talat Imran
Mr. Talat Imran
Chief Executive Officer, Director
Chief Executive Officer, Director
322.38K
+5.32%
Mr. Svai S. Sanford
Mr. Svai S. Sanford
Chief Financial Officer
Chief Financial Officer
187.34K
+1.34%
Mr. Jean-Luc Butel
Mr. Jean-Luc Butel
Independent Director
Independent Director
50.50K
--
Dr. Mir Hashim
Dr. Mir Hashim
Chief Scientific Officer
Chief Scientific Officer
28.90K
-85.44%
Ms. Kate Mckinley
Ms. Kate Mckinley
Chief Business Officer
Chief Business Officer
17.96K
--
Mr. Mir Imran
Mr. Mir Imran
Chairman of the Board
Chairman of the Board
--
--
Ms. Lisa Rometty
Ms. Lisa Rometty
Independent Director
Independent Director
--
--
Mr. Eric Groen
Mr. Eric Groen
General Counsel
General Counsel
--
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
--
--
Mr. Abraham (Abe) Bassan
Mr. Abraham (Abe) Bassan
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Talat Imran
Mr. Talat Imran
Chief Executive Officer, Director
Chief Executive Officer, Director
322.38K
+5.32%
Mr. Svai S. Sanford
Mr. Svai S. Sanford
Chief Financial Officer
Chief Financial Officer
187.34K
+1.34%
Mr. Jean-Luc Butel
Mr. Jean-Luc Butel
Independent Director
Independent Director
50.50K
--
Dr. Mir Hashim
Dr. Mir Hashim
Chief Scientific Officer
Chief Scientific Officer
28.90K
-85.44%
Ms. Kate Mckinley
Ms. Kate Mckinley
Chief Business Officer
Chief Business Officer
17.96K
--
Mr. Mir Imran
Mr. Mir Imran
Chairman of the Board
Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 10
Updated: Wed, Dec 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Samsara BioCapital, LLC
8.71%
RA Capital Management, LP
8.71%
South Lake One, LLC
2.44%
Imran (Mir A)
2.20%
Orca Capital GmbH
1.94%
Other
76.00%
Shareholders
Shareholders
Proportion
Samsara BioCapital, LLC
8.71%
RA Capital Management, LP
8.71%
South Lake One, LLC
2.44%
Imran (Mir A)
2.20%
Orca Capital GmbH
1.94%
Other
76.00%
Shareholder Types
Shareholders
Proportion
Venture Capital
17.98%
Investment Advisor
5.81%
Individual Investor
3.08%
Corporation
2.66%
Investment Advisor/Hedge Fund
0.59%
Hedge Fund
0.50%
Family Office
0.15%
Research Firm
0.08%
Other
69.14%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
76
8.12M
8.32%
+3.97M
2025Q2
83
12.26M
28.04%
-12.78M
2025Q1
84
12.65M
37.69%
-12.07M
2024Q4
85
12.92M
38.80%
-11.27M
2024Q3
87
18.82M
69.17%
+2.85M
2024Q2
85
16.05M
61.20%
-201.13K
2024Q1
83
16.40M
62.64%
+318.79K
2023Q4
84
15.94M
61.35%
-2.28M
2023Q3
87
15.75M
61.64%
-2.38M
2023Q2
85
15.77M
61.88%
-1.97M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
South Lake One, LLC
8.30M
17.33%
-3.83M
-31.57%
Oct 15, 2024
Orca Capital GmbH
1.89M
3.95%
+1.89M
--
Jul 22, 2025
The Vanguard Group, Inc.
799.68K
1.67%
--
--
Jun 30, 2025
Nan Fung Life Sciences
493.58K
1.03%
--
--
Jun 30, 2025
Citadel Advisors LLC
137.35K
0.29%
+137.35K
--
Jun 30, 2025
Imran (Talat)
306.10K
0.64%
+22.09K
+7.78%
Jun 27, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
Tema Heart & Health ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Tema Heart & Health ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Rani Therapeutics Holdings Inc?
The top five shareholders of Rani Therapeutics Holdings Inc are:
South Lake One, LLC holds 8.30M shares, accounting for 17.33% of the total shares.
Orca Capital GmbH holds 1.89M shares, accounting for 3.95% of the total shares.
The Vanguard Group, Inc. holds 799.68K shares, accounting for 1.67% of the total shares.
Nan Fung Life Sciences holds 493.58K shares, accounting for 1.03% of the total shares.
Citadel Advisors LLC holds 137.35K shares, accounting for 0.29% of the total shares.
South Lake One, LLC holds 8.30M shares, accounting for 17.33% of the total shares.
Orca Capital GmbH holds 1.89M shares, accounting for 3.95% of the total shares.
The Vanguard Group, Inc. holds 799.68K shares, accounting for 1.67% of the total shares.
Nan Fung Life Sciences holds 493.58K shares, accounting for 1.03% of the total shares.
Citadel Advisors LLC holds 137.35K shares, accounting for 0.29% of the total shares.
What are the top three shareholder types of Rani Therapeutics Holdings Inc?
The top three shareholder types of Rani Therapeutics Holdings Inc are:
Samsara BioCapital, LLC
RA Capital Management, LP
South Lake One, LLC
Samsara BioCapital, LLC
RA Capital Management, LP
South Lake One, LLC
How many institutions hold shares of Rani Therapeutics Holdings Inc (RANI)?
As of 2025Q3, 76 institutions hold shares of Rani Therapeutics Holdings Inc, with a combined market value of approximately 8.12M, accounting for 8.32% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -19.71%.
What is the biggest source of revenue for Rani Therapeutics Holdings Inc?
In --, the -- business generated the highest revenue for Rani Therapeutics Holdings Inc, amounting to -- and accounting for --% of total revenue.
